Loading...
Targeting Ovarian Cancer Cells Overexpressing CD44 with Immunoliposomes Encapsulating Glycosylated Paclitaxel
Paclitaxel (PTX) is one of the front-line drugs approved for the treatment of ovarian cancer. However, the application of PTX is limited due to the significant hydrophobicity and poor pharmacokinetics. We previously reported target-directed liposomes carrying tumor-selective conjugated antibody and...
Saved in:
| Published in: | Int J Mol Sci |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
MDPI
2019
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6429518/ https://ncbi.nlm.nih.gov/pubmed/30818864 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms20051042 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|